Suven Life Sciences Limited (BOM: 530239)
India
· Delayed Price · Currency is INR | Market Cap | 26.13B |
| Revenue (ttm) | 84.15M |
| Net Income (ttm) | -1.46B |
| Shares Out | 218.07M |
| EPS (ttm) | -6.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,792 |
| Open | 124.60 |
| Previous Close | 120.60 |
| Day's Range | 119.50 - 124.80 |
| 52-Week Range | 75.95 - 169.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 25, 2024 |
About Suven Life Sciences
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 recepto... [Read more]
Financial Performance
In 2023, Suven Life Sciences's revenue was 116.93 million, a decrease of -13.99% compared to the previous year's 135.95 million. Losses were -1.05 billion, -11.15% less than in 2022.
Financial StatementsNews
Suven Life Sciences reports positive Phase-2a results for Ropanicant in treating Major Depressive Disorder
Suven Life Sciences has recently informed exchanges about the positive topline results from its Phase-2a proof-of-concept signal detection open label fixed-dose study that assessed the safety and effi...
Suven Life Sciences announces FDA acceptance of Investigational New Drug
Suven Life Sciences, a clinical stage biopharmaceutical company that discovers and develops novel medicines to treat Central Nervous System (CNS) disorders, has recently announced that the United Stat...